ArticleJournal for immunotherapy of cancer2020
Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 63 citations in OpenAlex.
- The Role of B Cells in Tumorigenesis and Immunotherapy.Immune network · 2026Review
- Article
- Functional Suitability Evaluation of Radioimmunoconjugates of Nanobodies against PD-L1 and HER2/neu for Tumor Theranostics.Sovremennye tekhnologii v meditsine · 2026Article
- Precise combination therapy of radiotherapy and immunotherapy guided by joint PD-L1 imaging and T-cell imaging.Journal for immunotherapy of cancer · 2025Article
- Advances in Nanobody-Based Platforms for Precision Cancer Diagnosis and Therapy.Polymer science & technology (Washington, D.C.) · 2025Review
- Peptide-based immuno-PET/CT monitoring of dynamic PD-L1 expression during glioblastoma radiotherapy.Journal of pharmaceutical analysis · 2025Article
- Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy.European journal of nuclear medicine and molecular imaging · 2024Article
- Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.Journal of translational medicine · 2024Review
- Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.Journal of translational medicine · 2024Review
- Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.Journal of translational medicine · 2024Review
- Application ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review.Biomolecules & biomedicine · 2024Review
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- Detection of PD-L1 expression levels in malignant pleural mesothelioma with a targeted MRI nanoprobeFrontiers in chemistry · 2024Article
- Article
- Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.European journal of nuclear medicine and molecular imaging · 2023Article
- Implication ofJournal for immunotherapy of cancer · 2023Article
- Radioimmunotherapy study ofEJNMMI research · 2022Article
- Glucose-Thymidine Ratio as a Metabolism Index UsingInternational journal of molecular sciences · 2022Article
- Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.Nature reviews. Drug discovery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesStrategies to improve the responsiveness of programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade therapy remain an essential topic in cancer immunotherapy. In this study, we developed a new radiolabeled nanobody-based imaging probe
methodsThe binding affinity and specificity of nanobody MY1523 were measured in vitro. MY1523 was radiolabeled with
resultsMY1523 exhibited a high binding affinity and specificity to PD-L1 and had no competitive binding with the therapeutic antibody.
conclusionOur results demonstrated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.